MAY 11, 2017 6:20 AM PDT

First ALS Drug Approved in Over 2 Decades

WRITTEN BY: Xuan Pham

For the first time in over 20 years, the US Food and Drug Administration approved a new drug for the treatment of a disease commonly known as Lou Gehrig’s disease.

Known formally as amyotrophic lateral sclerosis (ALS), Lou Gehrig's disease is a fatal condition caused by the gradual breakdown and death of motor neurons in the spinal cord. All muscles under voluntary control are affected, causing muscle weakness and severe impairments in daily functions. There is no known cure and most ALS patients die from respiratory failure within 3 to 5 years from the onset of symptoms.

The new drug is known as Radicava or edaravone, and it was developed by Japanese Mitsubishi Tanabe Pharma. Trials for the drug conducted in Japan showed the drug slowed the progression of the disease. The 2015 phase 3 data from a six-month placebo-controlled study found the drug contributed to a 33 percent reduction in physical decline in ALS patients. So while the drug can’t reverse the trajectory of ALS, it could give patients just a little more time and freedom.

Interestingly, the FDA’s approval of the drug was based solely on data collected from the Japanese trial. These results were so compelling that the FDA worked with the company to file for US approval.

“After learning about the use of edaravone to treat ALS in Japan, we rapidly engaged with the drug developer about filing a marketing application in the United States,” said Eric Bastings, M.D., deputy director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “This is the first new treatment approved by the FDA for ALS in many years, and we are pleased that people with ALS will now have an additional option.”

Radicava is administered intravenously, with each infusion estimated to cost $1,086, and a year’s treatment costing $145,524 without assistance.

Prior to radicava, the 12-15,000 ALS patients had access to only one other approved ALS drug, riluzole by Sanofi. Riluzole was approved for ALS in 1995. Similar to radicava, the drug slows the progression of the disease, delaying the onset of ventilator-dependence and tracheotomy in some patients. The drug is estimated to prolong survival by two to three months.

For ALS patients and advocates, the approval of radicava marks a significant milestone. "We thank the FDA and MT Pharma for working together to expedite the approval of the first new ALS-specific treatment in decades," said ALS Association President Barbara Newhouse. "We hope (the) announcement signals the beginning of a new chapter in the fight against this terrible disease." The new drug is expected to come on the US market in August 2017.

Additional source: CNN

Image credit: pixabay.com

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUL 25, 2019
Clinical & Molecular DX
JUL 25, 2019
Tinea Versicolor, Diagnosis And Treatment
Tinea Versicolor (TV) is a fungal infection of the skin. Also called Pityriasis Versicolor, the condition is common, especially in tropical climates. The d...
SEP 08, 2019
Health & Medicine
SEP 08, 2019
Acute Flaccid Myelitis and Its Association With Enterovirus D68
Acute flaccid myelitis (AFM), a polio-like infection, caught the attention of physicians in the U.S. during late summer and early fall in 2014. The outbrea...
SEP 09, 2019
Clinical & Molecular DX
SEP 09, 2019
Brush Your Teeth for a Better Memory
What is good oral hygiene??? What will happen if you do not follow this important healthcare ritual? You are right.......DENTAL CAVITIES and GUM DISEASES.&...
DEC 09, 2019
Clinical & Molecular DX
DEC 09, 2019
Astronauts help to advanced personalized medicine
Extreme temperatures and lethal levels of radiation are just some of the hazards faced by astronauts as they traverse the harsh conditions of space. Additi...
JAN 07, 2020
Clinical & Molecular DX
JAN 07, 2020
Kiss and tell: new test for kissing bug disease
Here’s one Latin lover that you do not want to get kissed by: triatomines, or “kissing bugs”. Known locally as pitos or chipos, these ins...
JAN 06, 2020
Genetics & Genomics
JAN 06, 2020
Some Genetic Sequencing Tests Are Coming Up Short
If it's suspected that a person has a genetic disease, doctors might send the patient's DNA for sequencing. But some sequencing tests may not be checking thoroughly....
Loading Comments...